Medik8 has introduced Exo-PDRN Prismatic+, a 30ml serum that the brand says can reduce wrinkles, even tone and restore volume within a week... The formula blends a high‑strength exosome complex, GF MiniProtein and an ATP precursor, and the company points to clinical data showing measurable improvement after seven days of use.

Seven‑Day Clinical Study Shows Measurable Skin Gains

According to the product brief, a controlled study recorded statistically significant reductions in fine lines and increased firmness after just one week of daily application. The study, which the brand cites but does not fully disclose, forms the backbone of the “rapid results” claim that has sparked buzz among skincare enthusiasts.

Exosome Complex and GF MiniProtein Target Skin Resilience

The serum’s core actives include a high‑strength exosome complex and a GF MiniProtein, both marketed to work with the skin’s natural repair pathways. As the source notes, these ingredients are intended to boost resilience, a claim that aligns with broader trends of using cell‑derived technologies in luxury cosmetics.

ATP Precursor Added for Visible Rejuvenation

Medik8 highlights an ATP precursor as a third pillar of the formula, arguing that it fuels cellular energy and accelerates visible rejuvenation. The brand suggests that this component helps smooth texture and refresh the complexion , though independent verification of its efficacy remains limited .

Market Position: Medik8 Joins the PDRN Wave

PDRN, a Korean‑origin peptide that has become a buzzword for “glowing skin,” is now part of Medik8’s lineup, positioning the company alongside other brands that have recently adopted the ingredient. the source points out that Medik8 is best known for its retinal serum, and the new offering represents a strategic expansion into the PDRN segment.

Who’s Still Unclear? Independent Validation and Long‑Term Effects

While the brand cites a seven‑day study,the report does not name the research institution or disclose sample size, leaving questions about the robustness of the data.. Additionally, the long‑term safety and efficacy of combining exosomes, GF MiniProtein and an ATP precursor have not been independently confirmed.